Managed Care Reader Poll

Readers Believe Biosimilars Will Be Effective Against Costs


Whether biosimilars can turn the tide of rising pharmaceutical expenditures is yet to be seen, but Managed Care readers are optimistic about their chances.

In an online survey of readers conducted in late January and early February, 20% of the 113 respondents indicated that they believe that biosimilars will be highly effective in lowering drug costs, and the reader ratings of their effectiveness skewed positive.

There was slightly less belief in their effect on overall health care spending, with 16% indicating that biosimilars would be highly effective in blunting overall spending. On a scale of one to seven with seven being extremely effective, the respondents’ ratings averaged out at 4.2.

How effective will biosimilars be in lowering drug costs?

Scale 1-7, 1 = not at all effective, 7 = extremely effective

Which of the following is most likely to affect the size of the market for biosimilars?

In keeping with the expectations that biosimilars will influence costs, more than half (57%) of the respondents said the FDA and other regulatory agencies should be extremely active in encouraging the introduction and use of biosimilars, and 36% indicated that biosimilars should be interchangeable with their branded counterparts. Interchangeable means that a pharmacist can substitute the biosimilar for the branded product without the involvement of the prescribing physician. The respondents saw interchangeability regulations as the most important factor in determining the size of the biosimilar market

How active should the FDA and other regulatory agencies be in encouraging introduction and use of biosimilars?

Scale 1-7, 1 = not at all active, 7 = extremely active

Source for all charts: MediMedia Research

This reader survey was conducted by MediMedia Research, a unit of MediMedia Managed Markets, which owns Managed Care.

UP NEXT

Our Yearlong Look: Emergency Care Examined
By Robert Calandra

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report